In a recent study in type 2 diabetes the incidence of autoantibodies to apoA-1 was 37.5% in patients with cardiovascular disease (CVD) and patients who were autoantibody positive showed 5.7 times increased CVD risk [10]. This evidence concerns the gene APOA1 and type 2 diabetes mellitus.